Trabectedin A Review of its Use in Soft Tissue Sarcoma and Ovarian Cancer
Trabectedin A Review of its Use in Soft Tissue Sarcoma and Ovarian Cancer
复制标题
DOI：
10.2165/11202860-000000000-00000
复制
发表时间：
2010-01-01
期刊：
影响因子：
11.5
通讯作者：
Keam, Susan J.
中科院分区：
文献类型：
--
作者：
Carter, Natalie J.;Keam, Susan J.
Trabectedin（Yondelis（R））是一种最初来源于海洋生物的四氢异喹啉分子。在欧盟和许多其他国家，其适用于既往接受过蒽环类和异环磷酰胺治疗但病情进展的晚期软组织肉瘤（STS）患者或无法接受这些药物治疗的患者。它也在欧盟被批准与聚乙二醇化脂质体多柔比星联合用于治疗铂敏感性复发性卵巢癌。此外，trabectedin在美国、瑞士和韩国是治疗晚期、复发性STS的孤儿药，在美国和瑞士也是治疗晚期、复发性卵巢癌的孤儿药。临床试验表明，静脉注射trabectedin对有化疗经验的晚期、复发性脂肪肉瘤或平滑肌肉瘤患者有效，一项回顾性分析的结果表明，该药物可能对晚期粘液样脂肪肉瘤患者特别有效。此外，在一线铂类化疗失败后复发性卵巢癌患者中，与聚乙二醇脂质体多柔比星单药治疗相比，曲贝替丁与聚乙二醇脂质体多柔比星联合给药与显著更长的无进展生存期（6周）相关。在临床试验中，trabectedin的耐受性特征是可管理的，同时使用trabectedin和聚乙二醇化脂质体多柔比星的耐受性特征通常与每种药物单独使用的耐受性特征一致。迄今为止的结果表明，曲贝替定是一个有价值的除了组的二线化疗药物可用于治疗晚期，复发性STS，它是一个有益的治疗复发性卵巢癌后，一线，铂为基础的化疗失败时，与聚乙二醇脂质体阿霉素联合给药。
Trabectedin (Yondelis (R)) is a tetrahydroisoquinoline molecule that was originally derived from a marine organism. It is indicated in the EU and many other countries for use in patients with advanced soft-tissue sarcoma (STS) who have progressed despite receiving previous treatment with anthracyclines and ifosfamide or in those who are unable to receive these agents. It is also approved in the EU in combination with pegylated liposomal doxorubicin for the treatment of platinum-sensitive, recurrent ovarian cancer. In addition, trabectedin holds orphan drug status for the treatment of advanced, recurrent STS in the US, Switzerland and Korea, and for the treatment of advanced, recurrent ovarian cancer in the US and Switzerland.Clinical trials showed that intravenous trabectedin was effective in chemotherapy-experienced patients with advanced, recurrent liposarcoma or leiomyosarcoma, and results from a retrospective analysis suggest that the drug may be particularly effective in patients with advanced myxoid liposarcoma. In addition, coadministration of trabectedin with pegylated liposomal doxorubicin was associated with a significantly longer progression-free survival (6 weeks) than pegylated liposomal doxorubicin monotherapy in patients with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. The tolerability profile of trabectedin was manageable in clinical trials, and the tolerability profile of concomitant trabectedin and pegylated liposomal doxorubicin was generally consistent with that of each agent alone. Results to date indicate that trabectedin is a valuable addition to the group of second-line antineoplastic agents available for the treatment of advanced, recurrent STS, and that it is a beneficial treatment for recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy when administered in conjunction with pegylated liposomal doxorubicin.